These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16261619)

  • 1. Augmentation of artistic productivity in Parkinson's disease.
    Walker RH; Warwick R; Cercy SP
    Mov Disord; 2006 Feb; 21(2):285-6. PubMed ID: 16261619
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 3. CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study.
    Olanow CW; Werner EG; Gauger LL
    Clin Neuropharmacol; 1989 Dec; 12(6):490-7. PubMed ID: 2575014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sinemet in Parkinson's disease: efficacy with and without food.
    Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB
    Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604
    [No Abstract]   [Full Text] [Related]  

  • 5. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
    Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761
    [No Abstract]   [Full Text] [Related]  

  • 6. Off-period screaming accompanying motor fluctuations in Parkinson's disease.
    Steiger MJ; Quinn NP; Toone B; Marsden CD
    Mov Disord; 1991; 6(1):89-90. PubMed ID: 2005932
    [No Abstract]   [Full Text] [Related]  

  • 7. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical studies with levodopa/carbidopa intestinal gel].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2014 Jan; 67(1-2):5-8. PubMed ID: 24654442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
    Wolters EC; Horstink MW; Roos RA; Jansen EN
    Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage.
    Munro Neville A; Parsons RW; Askmark H; Nyholm D
    Parkinsonism Relat Disord; 2012 Jun; 18(5):686-7. PubMed ID: 22197121
    [No Abstract]   [Full Text] [Related]  

  • 11. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease.
    Avanzi M; Uber E; Bonfà F
    Neurol Sci; 2004 Jun; 25(2):98-101. PubMed ID: 15221629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug therapy of patients with early-stage parkinson's disease].
    Kondo T
    Nihon Rinsho; 2000 Oct; 58(10):2055-60. PubMed ID: 11068446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amantadine-induced "vocal" myoclonus.
    Pfeiffer RF
    Mov Disord; 1996 Jan; 11(1):104-6. PubMed ID: 8771080
    [No Abstract]   [Full Text] [Related]  

  • 14. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First emergence of "delayed-on" and "dose failure" phenomena in a patient with Parkinson's disease following vagotomy.
    Djaldetti R; Achiron A; Ziv I; Melamed E
    Mov Disord; 1994 Sep; 9(5):582-3. PubMed ID: 7990855
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nyholm D; Jansson R; Willows T; Remahl IN
    Neurology; 2005 Nov; 65(9):1506-7. PubMed ID: 16275852
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopamine dysregulation syndrome and punding in levodopa-carbidopa intestinal gel (LCIG) infusion: A serious but preventable complication.
    Salomone G; Marano M; di Biase L; Melgari JM; Di Lazzaro V
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1124-5. PubMed ID: 26242552
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of carbidopa as an adjuvant to levodopa/carbidopa therapy in patients with Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Pasternack P
    N Y State J Med; 1986 Dec; 86(12):655-6. PubMed ID: 3468386
    [No Abstract]   [Full Text] [Related]  

  • 19. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease.
    Westin J; Nyholm D; Groth T; Dougherty MS; Yerramsetty PK; Palhagen SE
    Parkinsonism Relat Disord; 2006 Dec; 12(8):509-13. PubMed ID: 16731025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.